A Phase III clinical trial of the first fully individualized mRNA cancer vaccine produced a sixty-two percent reduction in cancer recurrence rates among melanoma patients compared to standard immunotherapy alone, according to results presented at the American Society of Clinical Oncology’s annual congress on Friday. The findings, described by senior oncologists in attendance as among the most significant in cancer immunology in a generation, are expected to support regulatory submissions for approval in the United States and European Union before the end of this year.
The vaccine platform, developed jointly by Moderna and Merck, works by sequencing the genetic mutations specific to each individual patient’s tumor and encoding neoantigens — protein fragments unique to the cancer cells — into an mRNA construct that is manufactured and administered within approximately six weeks of biopsy. The immune system learns to recognize these specific markers and mounts a surveillance response targeting remaining cancer cells carrying identical mutations, while leaving healthy tissue unaffected because the targeted sequences do not appear in normal cells.
The trial enrolled more than one thousand patients across fourteen countries, all of whom had undergone surgical removal of high-risk melanoma and were receiving standard checkpoint inhibitor immunotherapy as part of their post-operative protocol. Half received the personalized vaccine in addition; half received immunotherapy alone. After a median follow-up of thirty-four months, the vaccine group showed dramatically superior recurrence-free survival curves that statisticians confirmed were highly unlikely to reflect chance variation.
Side effect profiles were manageable, with the most common adverse events being injection site reactions and temporary flu-like symptoms — findings that support the vaccine’s favorable benefit-risk profile. Oncologists noted that the platform’s approach is theoretically applicable beyond melanoma to other solid tumor types, with lung cancer and bladder cancer trials already underway using the same individualized manufacturing process.
Manufacturing at scale remains a logistical and cost challenge, but the developers indicated that process improvements have reduced per-dose manufacturing costs by more than forty percent since the trial began.